Načítá se...
The Impact of Metformin Use on the Cardiovascular Effects of DPP-4 Inhibitors: an Analysis of Medicare Claims Data 2007–2015
AIMS: Metformin may moderate cardiovascular outcomes with dipeptidyl peptidase-4 inhibitors (DPP-4i). We examined outcomes of DPP-4i initiation with and without concurrent metformin. MATERIALS AND METHODS: We identified Medicare enrollees initiating DPP-4i, sulfonylurea, or thiazolidinedione. Using...
Uloženo v:
| Vydáno v: | Diabetes Obes Metab |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6527500/ https://ncbi.nlm.nih.gov/pubmed/30456843 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13589 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|